Bio-Rad Expands Its Multiplex Immunoassays with the Launch of Bio-Plex Pro™ Human Apolipoprotein Panel


Assay Offers Largest Set of Apolipoproteins Commercially Available

Bio-Plex Pro Human Apolipoprotein Panel

The Bio-Plex Pro Human Apolipoprotein Panel offers sensitive detection of nine key apolipoproteins and C-reactive protein in human samples to help researchers gain new insights into cardiovascular and neurological diseases.

HERCULES, CA — May 1, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro™ Human Apolipoprotein Panel. This 10-plex panel allows researchers to rapidly detect and quantify key human apolipoproteins associated with cardiovascular disease, especially within the statin pathway, as well as the widely used biomarker C-reactive protein. The panel, which offers the largest number of apolipoproteins on the market, includes four targets (Apo C1, Apo D, Apo J, and Apo H) not found on other multiplex panels.

“The Bio-Plex Pro Apolipoprotein Panel is not only the most comprehensive apolipoprotein assay available, it also allows researchers to detect more samples than any other assay on the market, leading to clear and actionable results,” said Brett Houser, Bio-Plex Global Product Manager, Bio-Rad.

Detecting changes in apolipoprotein levels can be difficult with traditional ELISA techniques because they require a large sample input. The Bio-Plex Pro Apolipoprotein Panel offers a multiplex solution with low sample requirements to accommodate the study of precious samples.

In addition, the panel allows researchers to measure the level of C-reactive protein, a commonly used biomarker for a wide range of conditions, in the same assay as apolipoproteins, and it can assess how these different analytes work in concert in the human body.

For scientists in both biopharma and academia exploring cholesterol metabolism and the statin pathway, the panel facilitates the robust, sensitive, and high-throughput study of a variety of apolipoproteins across many disease areas, including cardiovascular and neurological disease, hypercholesterolemia, diabetes, obesity, and sepsis.

Notable benefits of the Bio-Plex Pro Apolipoprotein Panel include:

  1. High sample detectability — enables detection of more samples than any other available assay, allowing researchers to get more data out of each run
  2. Premixed, ready-to-use reagents — saves time and simplifies workflow with clear instructions
  3. Streamlined data analysis — includes Bio-Plex Manager™ and Bio-Plex Data Pro™ Software for efficient analysis and data management

The Bio-Plex Pro Apolipoprotein Panel is a ready-to-use, 1 x 96-well kit containing premixed magnetic capture beads and detection antibodies, standards, and buffers. The panel is compatible with platforms including the Bio-Plex® 200, Bio-Plex 3D, Bio-Plex® MAGPIX™, and all Luminex platforms.

For more information about Bio-Rad’s Bio-Plex product portfolio, please visit

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products and our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Legal notice:
xMAP, Luminex, and MAGPIX are trademarks of Luminex Corporation. The Bio-Plex suspension array system includes fluorescently labeled microsphere and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.

Press contact:
Bio-Rad Laboratories, Inc.
Brett Houser

CG Life
Ken Li